First-Line Pharmacologic Treatment for Restless Legs Syndrome
For adults with RLS, gabapentin, pregabalin, or gabapentin enacarbil are the first-line pharmacologic treatments, with strong recommendations from the 2025 AASM guidelines. 11
Treatment Algorithm
Step 1: Check Iron Status First
Before initiating any pharmacologic therapy, assess iron parameters. Iron therapy should be considered first-line when ferritin is <75 ng/mL, with a goal of >100 ng/mL 23. This differs from standard population guidelines and reflects iron's critical role in RLS pathophysiology.
- IV ferric carboxymaltose receives a strong recommendation (moderate certainty evidence) 11
- Oral ferrous sulfate receives a conditional recommendation (moderate certainty evidence) 11
- Other IV formulations (iron dextran, ferumoxytol) have conditional recommendations with lower certainty 1
Step 2: First-Line Pharmacologic Agents (α2δ Calcium Channel Ligands)
If iron therapy alone is insufficient or iron stores are adequate, initiate:
Strong recommendations (moderate certainty evidence):
These agents are now preferred over dopamine agonists due to superior long-term safety profiles and absence of augmentation risk 245.
Critical Paradigm Shift: Dopamine Agonists Are No Longer First-Line
The 2025 AASM guidelines represent a major departure from 2012 recommendations by suggesting AGAINST standard use of all dopamine agonists 111:
- Pramipexole: conditional recommendation AGAINST (moderate certainty) 11
- Ropinirole: conditional recommendation AGAINST (moderate certainty) 11
- Rotigotine: conditional recommendation AGAINST (low certainty) 11
- Levodopa: conditional recommendation AGAINST (very low certainty) 11
Why This Change?
The primary concern is augmentation—a paradoxical worsening of RLS symptoms with long-term dopaminergic therapy, occurring earlier in the day, with greater intensity, and spreading to other body parts 267. While dopaminergics remain effective short-term, their long-term risk-benefit profile is unfavorable for chronic management 67.
Remarks in guidelines: Dopamine agonists may still be considered for patients who prioritize short-term symptom reduction over long-term augmentation risk, but this should be the exception, not the rule 11.
Common Pitfalls to Avoid
Don't skip iron assessment: Even without anemia, brain iron deficiency is central to RLS pathophysiology. Target ferritin >100 ng/mL, not just >50 ng/mL as in general populations 23.
Don't start with dopamine agonists: Despite their historical use and short-term efficacy, augmentation risk makes them inappropriate for routine first-line therapy 257.
Address exacerbating factors: Remove antihistamines, SSRIs, SNRIs, antipsychotics, and treat comorbid sleep apnea before escalating pharmacotherapy 1.
Avoid benzodiazepines as first-line: Clonazepam receives a conditional recommendation AGAINST use 11.
Special Populations
End-Stage Renal Disease (ESRD)
- Gabapentin: conditional recommendation (very low certainty) 1
- IV iron sucrose: conditional recommendation when ferritin <200 ng/mL and transferrin saturation <20% (moderate certainty) 11
Pregnancy
Consider pregnancy-specific safety profiles; iron therapy is generally preferred 1.
Children
Ferrous sulfate receives conditional recommendation when iron stores are low (very low certainty) 11.
Second-Line and Refractory Disease
When α2δ ligands are insufficient:
- Extended-release oxycodone and other opioids: conditional recommendation (moderate certainty) 111
- Dipyridamole: conditional recommendation (low certainty) 11
- Bilateral high-frequency peroneal nerve stimulation: conditional recommendation (moderate certainty) 11
Medications to Avoid
Strong recommendation AGAINST:
Conditional recommendations AGAINST:
The evidence is clear and consistent: α2δ ligands (gabapentin, pregabalin, gabapentin enacarbil) combined with appropriate iron repletion represent the modern first-line approach to RLS pharmacotherapy, marking a fundamental shift away from dopaminergic agents that dominated treatment for decades 11257.